Mandate

Vinge has advised Amasten Fastighets AB in connection with a directed share issue

September 15, 2020 Capital Markets and Public M&A

Vinge has advised Amasten Fastighets AB (“Amasten”), a real estate company, in connection with a directed share issue whereby Amasten receives SEK 500 million in issue proceeds.

The subscription price was determined to SEK 7.30 per share through an accelerated book building process. The share issue was directed to selected Swedish and international investors. The main purpose of the share issue is to finance continued growth through acquisitions of investment properties and development projects.

Vinge’s team consisted of Jesper Schönbeck, Rikard Lindahl, Malte St Cyr Ohm and Amanda M Johansson.

 

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025